Emcure Pharmaceuticals partners with Novo Nordisk India to launch Poviztra®, a semaglutide injection 2.4 mg, for weight loss in India. This collaboration makes Emcure the first Indian company with exclusive rights to distribute and commercialize Poviztra®. This partnership aims to broaden access to semaglutide treatments for weight management, complementing Novo Nordisk’s existing Wegovy® offering and addressing a significant unmet need.
Strategic Collaboration
Emcure Pharmaceuticals and Novo Nordisk India have announced a strategic partnership to launch Poviztra® (semaglutide injection 2.4 mg) in India, effective November 10, 2025. The collaboration aims to strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions currently not served by Novo Nordisk India.
Poviztra®: A Second Brand of Wegovy®
Poviztra® will be the second brand of Wegovy® available in India. Wegovy®, launched in June 2025, is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management and reduction in cardiovascular risk. Clinical trials showed that 1 in 3 participants on Wegovy® experienced weight loss of over 20%.
Expanded Access to Treatment
The partnership aligns with Novo Nordisk India’s efforts to ensure its treatments reach a greater number of patients, expanding access to effective weight management medication. As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialization and marketing of Poviztra® (semaglutide injection 2.4 mg) in India.
Executive Commentary
Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk, highlighted that obesity affects millions in India with significant unmet medical needs and that this partnership broadens access to high-quality obesity treatment.
Source: BSE
